← Back to patent-cliff list
CAS 869366-70-1
tert-butyl (3-(4-chloro-2-(2-fluoro-6-methoxybenzoyl)phenyl)prop-2-yn-1-yl)carbamate
Codes: ALISE-005
Application context (from source-drug indications)
Breast cancerAlisertibMetastatic breast cancerAlisertibSmall cell lung cancerAlisertibSolid tumourAlisertibHead and neck squamous cell carcinomaAlisertib横纹肌样瘤Alisertib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Alisertib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(2-amino-5-chlorophenyl)(2,6-difluorophenyl)methanone→(5-chloro-2-iodophenyl)(2,6-difluorophenyl)methanone→(5-chloro-2-iodophenyl)(2-fluoro-6-methoxyphenyl)methanone→tert-butyl prop-2-yn-1-ylcarbamate→tert-butyl (3-(4-chloro-2-(2-fluoro-6-methoxybenzoyl)phenyl)prop-2-yn-1-yl)carbamate→(Z)-8-chloro-4-((dimethylamino)methylene)-1-(2-fluoro-6-methoxyphenyl)-3H-benzo[c]azepin-5(4H)-one→4-guanidino-2-methoxybenzoic acid hydrochloride→prop-2-yn-1-amine→methyl 4-amino-2-methoxybenzoate→4-guanidino-2-methoxybenzoic acid
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.